Dr. Margarita Stoytcheva
Background: Detecting early signs of Alzheimer’s disease (AD) and mild cognitive impairment (MCI) during the pre-symptomatic phase is becoming increasingly important for costeffective clinical trials and also for deriving maximum benefit from currently available treatment strategies. However, distinguishing early signs of MCI from normal cognitive aging is difficult. Biomarkers have been extensively examined as early indicators of the pathological process for AD, but assessing these biomarkers is expensive and challenging to apply widely among pre-symptomatic community dwelling older adults. Here we propose assessment of social markers, which could provide an alternative or complementary and ecologically valid strategy for identifying the pre-symptomatic phase leading to MCI and AD.
Read the complete article here: http://bit.ly/1J2c9hW
Current Protein & Peptide Science publishes review articles on specific aspects involving proteins, peptides, and interactions between the enzymes, the binding interactions of hormones and their receptors; the properties of transcription factors and other molecules that regulate gene expression; the reactions leading to the immune response; the process of signal transduction; the structure and function of proteins involved in the cytoskeleton and molecular motors; the properties of membrane channels and transporters; and the generation and storage of metabolic energy. In addition, reviews of experimental studies of protein folding and design are given special emphasis. Manuscripts submitted to Current Protein and Peptide Science should cover a field by discussing research from the leading laboratories in a field and should pose questions for future studies. Original papers, research articles and letter articles/short communications are not considered for publication in Current Protein & Peptide Science.
Following are the articles from the journal Current Protein & Peptide Science, 16 Issue 5:
Editorial: (Thematic Issue: Hormonal Crosstalk in Plants: The Ultimate Determiner of Plant Fate)
Author(s): Golam Jalal Ahammed
Article: The Common Molecular Players in Plant Hormone Crosstalk and Signaling
Author(s): Puja Ohri, Renu Bhardwaj, Shagun Bali, Ravinderjit Kaur, Shivam Jasrotia, Anjali Khajuria and Ripu D. Parihar
Article: Auxin Crosstalk to Plant Immune Networks: A Plant-Pathogen Interaction Perspective
Author(s): Muhammad Naseem, Mugdha Srivastava, Muhammad Tehseen and Nazeer Ahmed
Article: Phytohormone Crosstalk Research: Cytokinin and its Crosstalk with Other Phytohormones
Author(s): Samir A. Seif El-Yazal, Mohamed A. Seif El-Yazal, Emad F. Dwidar and Mostafa M. Rady
Article: Gibberellins – A Multifaceted Hormone in Plant Growth Regulatory Network
Author(s): Saikat Gantait, Uma Rani Sinniah, Md. Nasim Ali and Narayan Chandra Sahu
Article: Abscisic Acid: A Versatile Phytohormone in Plant Signaling and Beyond
Author(s): Aurelio Gomez-Cadenas, Vicente Vives, Sara I. Zandalinas, Matias Manzi, Ana M. Sanchez-Perez, Rosa M. Perez-Clemente and Vicent Arbona
Article: Role of Various Hormones in Photosynthetic Responses of Green Plants Under Environmental Stresses
Author(s): Poonam, Renu Bhardwaj, Ravdeep Kaur, Shagun Bali, Parminder Kaur, Geetika Sirhindi, Ashwani K. Thukral, Puja Ohri and Adarsh P. Vig
Article: Crosstalk among Jasmonate, Salicylate and Ethylene Signaling Pathways in Plant Disease and Immune Responses
Author(s): You-Xin Yang, Golam J. Ahammed, Caijun Wu, Shu-ying Fan and Yan-Hong Zhou
Article: Role of Brassinosteroid in Plant Adaptation to Abiotic Stresses and its Interplay with Other Hormones
Author(s): Golam J. Ahammed, Xiao-Jian Xia, Xin Li, Kai Shi, Jing-Quan Yu and Yan-Hong Zhou
For details, please visit: http://bit.ly/1KSHbod
Current Pharmaceutical Analysis publishes expert reviews and original research articles on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis, analytical methodology and instrumentation. The journal is essential to all involved in pharmaceutical, biochemical and clinical analysis.
Author(s): Mate Somlyay, Gabor Orgovan and Bela Noszal
Article: Application of Droplet Size Analysis for the Determination of the Required HLB of Lemon Oil in O/W Emulsion
Author(s): N.A. Niczinger, N. Kallai-Szabo, J. Dredan, L. Budai, M. Hajdu and I. Antal
Article: Electrochemical Analysis of Cyanuric Acid Using Polyaniline/CuGeO3 Nanowires as Electrode Modified Materials
Author(s): L.Z. Pei, H.D. Liu, N. Lin, Y.K. Xie and Z.Y. Cai
Article: Simultaneous Analysis of Losartan Potassium and its Related Impurities and Degradation Products in Tablets Using HPLC
Author(s): Shuhong Qiu, Kai Liu, Panqin Ma, Menglin Wang, Hongming Chen, Xiaochao Xu, Xiaoli Hao and Yongjun Wang
Article: LC-MS/MS Assay for Quantification of a Novel Antitubercular Molecule S006-830: Pharmacokinetic and Plasma Protein Binding Studies in Rats
Author(s): Mahendra Kumar Hidau, Yeshwant Singh, Sudhir Shahi, Poojari Mounika and Shio Kumar Singh
Article: Method Development & Validation of LCMS/MS for Atorvastatin and Olmesartan in Human Plasma to Trace Drug Interaction of Formulation
Author(s): Rakesh Das and T.K. Pal
Article: The Effect of Albumin-genotype on Ibuprofen Displacement of Nifedipine from its Binding Sites.
Author(s): Eman Atef and Ahmed S. Mehanna
Article: High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction
Author(s): Andreja Trpkovic, Julijana Stanimirovic, Ivana Resanovic, Petar Otasevic, Danimir Jevremovic, Radak Djordje and Esma R. Isenovic
Article: Analysis of Tocopherols and Tocotrienols in Pharmaceuticals and Foods: A Critical Review
Author(s): Dan Lu, Yi Yang, Yongxin Li and Chengjun Sun
For details, please visit: http://bit.ly/1BjtM3A
For any information, visit: http://benthamscience.com/journal/index.php?journalID=aps
Letters in Organic Chemistry, 11 Issue 9
Aims & Scope
Letters in Organic Chemistry publishes original letters, mini-reviews and guest edited issue in all areas of organic chemistry including synthesis, bioorganic, medicinal, natural products, organometallic, supramolecular, molecular recognition and physical organic chemistry. The emphasis is to publish quality papers rapidly by taking full advantage of latest technology for both submission and review of the manuscripts.
The journal is an essential reading for all organic chemists belonging to both academia and industry.
Abstracted & Indexed in:
Science Citation Index ExpandedTM, Journal Citation Reports/Science Edition, ISI Alerting ServicesTM, Current Contents®/Physical, Chemistry Citation Index®, Scopus, Chemical Abstracts, Chemical and Earth Sciences, PubsHub, GenamicsJournalSeek, MediaFinder®-Standard Periodical Directory, Reaxys, J-Gate.
For more details please visit: http://benthamscience.com/journal/index.php?journalID=loc
CNS & Neurological Disorders – Drug Targets , 13 Issue 6
Aims & Scope
CNS & Neurological Disorders – Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes.
CNS & Neurological Disorders – Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies.
As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
Abstracted & Indexed in:
Science Citation Index Expanded, MEDLINE, PubMed, BIOSIS, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Chemical Abstracts, EMBASE/ExcerptaMedica, PsycINFO, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, Scopus, Neuroscience Citation Index®, MediaFinder®-Standard Periodical Directory, GenamicsJournalSeek, PubsHub, J-Gate.
For more details please visit: http://benthamscience.com/journal/index.php?journalID=cnsnddt
One of our respected Editorial Board Members of Bentham Science journal ‘Combinatorial Chemistry & High Throughput Screening’ , Rakesh Rathore, has contributed to the implementation of mass spectrometry-based high-throughput screening technologies to identify drug leads and made us all very proud of him:
Focus On Research With Rakesh Rathore, PhD
|After a receiving his PhD in biochemistry from Govind Ballabh Pant University and his master’s degree from Cancer Hospital & Research Institute, both in India, Rakesh Rathore conducted postdoctoral research in the Department of Biochemistry & Biophysics at Göteborg University in Sweden and then the Center for Cardiovascular Sciences at Albany Medical Center. Rathore is currently working as a research scientist within the Proteomics & Mass Spectrometry Core Laboratory and the Department of Cancer Biology at UC.He is involved in implementing mass spectrometry-based high-throughput screening technologies to identify drug leads. Mass spectrometry is a tool that can be effectively used to detect ionizable elements in a wide variety of sample types in the form of mass to charge ratio. Mass spectrometry-based assays offer a rapid, sensitive and direct approach to measure the effects on enzyme activity.He also oversees the operation of the UC diverse pharmaceutical compound repository, which consists of over 350,000 compounds.
He serves as reviewer and editorial advisory board member in drug discovery and development journals, including the Combinatorial Chemistry & High Throughput Screening and the Journal of Bimolecular Screening.What brought you to UC?“I was looking for new technology development opportunities after several years of conducting calcium signaling basic research at Albany Medical Center, and at the same time, my wife assumed a fellowship at a Dayton-based health care system. So we decided to move to this area, where I obtained a research position in the Proteomics & Mass Spectrometry Laboratory with Ken Greis, PhD, on a drug discovery technology project which was funded by MDS Analytical Technologies in Canada. Since industry is currently taking part in many collaborative research efforts with academia, this unique position made my move to UC a great professional opportunity. This area turns out to be a great place to raise a family, and we have been here for about six years.”What is the focus of your research? What discoveries have you made?“My focus of research is on mass spectrometry-based enzyme assay development and high-throughput screening technologies for drug discovery applications, and we have developed a new mass spectrometry-based tool that provides more precise, cost-effective data collection for drug discovery.
“Using robotics, data processing and control software, liquid handling devices, and sensitive detectors, high-throughput screening allows a researcher to quickly conduct millions of chemical, genetic or pharmacological tests. Through this process one can rapidly identify active compounds which modulate a particular biomolecular pathway. The results of these experiments provide starting points for drug design and for understanding the interaction or role of a particular biochemical process in biology.
“Recently we have extended our capabilities to screen more than 30,000 compounds with mass spectrometry and compared our results with conventional fluorescence methods, which is part of a National Cancer Institute-funded Innovative Molecular Analysis Technologies grant with Dr. Greis. We obtained interesting data to help understand how one can improve the chances of obtaining hits more likely to succeed in clinical trials, which would have been missed using traditional methods of screening. This has the potential of changing the way drug discovery research is performed.
“We further extended this technology to develop a fee for service model for other investigators that was demonstrated by 25,000 compounds screened for a group at Case Western Reserve University. Now, we can offer targeted screening of 1,000 to 5,000 compounds as a revenue source for core facility.
“This year, the work was recognized as a finalist of the Waters Corporation poster award during the 2013 Association of Biomolecular Resource Facilities conference and in the ‘Gallery Of Excellence’ at UC Research Day 2013.
“At UC, I worked on a Global Cardiovascular Innovation Center grant to the company CardioCeption, LLC, founded by Keith Jones, PhD, and part of the UC Tech Accelerator, which was involved in the pre-clinical studies in various cardiovascular conditions.”
How will this impact patient care?
“Drug discovery is the perfect bridge between basic and clinical research. We are one of very few research institutes to have a library of over 350,000 compounds, which enables us to screen many new and existing drug targets for new leads with the potential for new therapeutics. From our own data using this library, we obtained promising hits and are further evaluating the results, which may have the potential to impact patient care through the development of successful drugs in the future.”
What do you like to do in your spare time?
“I mainly enjoy spending time with my family and friends and traveling. I have a 3-year-old daughter who loves playing with me, thus my evening time is quite different from what I do at UC. I have been involved with United Way activities in the recent past and would like to continue such services to similar nonprofit organizations.”
Borrowed from http://healthnews.uc.edu/news/?/23525/